A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Major challenge for enrollment of participants.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: INC280 single agent
DRUG: erlotinib

Sponsor

Novartis Pharmaceuticals